Genera Biosystems said this week that the Australian Therapeutic Goods Administration has approved its PapType human papillomavirus test kit for inclusion in the Australian Register of Therapeutic Goods.

PapType is a PCR-based assay, which uses Genera's AmpaSand beads as "microscale platforms upon which DNA hybridization events can occur," the company said. Binding events on the beads are read by flow cytometer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.